- biomarkers, cancer, chronic disease, diabetes, epidemiology, global health, nutrition, overweight & obesity, physical activity, prevention
Dr. Toriola’s research focuses on characterizing the molecular basis, and determinants of mammographic breast density and breast cancer in order to identify those that can be targeted in breast cancer prevention, especially in premenopausal women. He is the Principal Investigator on 2 R01s (R37CA23560, R01CA246592) and an R21 (R21CA216515) on mammographic breast density. In addition to his NIH/NCI funded phase II clinical trial investigating the effect of RANKL inhibition on mammographic breast density and breast tissue/blood markers in premenopausal women with dense breasts (R37CA235602: https://clinicaltrials.gov/ct2/show/NCT04067726), he is also using state of the art metabolomics platforms to interrogate the metabolite profiles of mammographic breast density in premenopausal women (R01CA246592).
In addition, he performs molecular epidemiologic studies on colorectal and pancreatic cancers, evaluating the utility of biomarkers to investigate the associations of energetics, and inflammation with risk/mortality. He is an MPI on the ColoCare Study (U01 CA206110: https://clinicaltrials.gov/ct2/show/NCT02328677), a large multicenter cohort of colorectal cancer (CRC) patients for interdisciplinary studies of CRC prognosis and outcomes.